COCH Envoy Medical, Inc.
Legal ·
Atlas Merchant Capital agreed to dismiss its Chancery Court claims with prejudice, the hearing health company says. Two former executives were also named as defendants.
Nasdaq said Envoy did not regain compliance with its $35,000,000 market value of listed securities requirement. A hearing request filed August 29, 2025 stays any trading suspension.
Nasdaq says the market value of Envoy Medical's listed securities did not meet the minimum for 31 consecutive business days. The company has until August 25, 2025 to regain compliance.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $241,000 | $225,000 |
| Research and development | $12.5 million | $10.2 million |
| Net income (loss) | -$23.8 million | -$20.8 million |
| Cash from operations | -$18.2 million | -$17.9 million |
| Cash and equivalents | $3.7 million | $5.5 million |
Our latest story on this, dated Aug 29, 2025: "Envoy Medical asks Nasdaq panel to review delisting determination on market value rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 3, 2025: "Envoy Medical receives Nasdaq deficiency notice on $35,000,000 market value requirement". The story links the filing or release it is based on. Read the story.
Envoy Medical, Inc. trades under the ticker COCH on NASDAQ.
Envoy Medical, Inc. is listed on NASDAQ.
Our directory records Envoy Medical, Inc. under United States.
aibio.space lists Envoy Medical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$241,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Envoy Medical, Inc. reported a net loss of $23.8 million for the fiscal year ended Dec 31, 2025, and used $18.2 million of cash in operations, per its annual report to the SEC.
$12.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$19.7 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Envoy Medical, dated Oct 7, 2026: "Envoy Medical ends Atlas SPAC redemption suit in Delaware with no payment". Atlas Merchant Capital agreed to dismiss its Chancery Court claims with prejudice, the hearing health company says. Two former executives were also named as defendants. Source.
From our story of Oct 7, 2026: Envoy's 10-Q says its history of negative operating cash flows and losses raises substantial doubt about its ability to continue as a going concern, and that management's plans do not alleviate that doubt. Source.
Our latest legal story, dated Oct 7, 2026: "Envoy Medical ends Atlas SPAC redemption suit in Delaware with no payment". Atlas Merchant Capital agreed to dismiss its Chancery Court claims with prejudice, the hearing health company says. Two former executives were also named as defendants. Claims in lawsuits are allegations until a court rules. Source.
Press Follow on this page to add Envoy Medical to your Following list, or subscribe to the aibio.space newsletter. We have published 3 stories naming Envoy Medical so far, in Legal, Listings.
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio